Uniunea Europeană - română - EMA (European Medicines Agency)

eli lilly nederland b.v. - ramucirumab - neoplasme de stomac - agenți antineoplazici - gastric cancercyramza în combinație cu paclitaxel este indicat pentru tratamentul pacienților adulți cu cancer gastric avansat sau gastro-esofagian adenocarcinom de joncțiune cu progresia bolii după înainte de platină și fluoropirimidină chimioterapie. cyramza este indicat în monoterapie pentru tratamentul pacienților adulți cu cancer gastric avansat sau gastro-esofagian adenocarcinom de joncțiune cu progresia bolii după înainte de platină sau fluoropirimidină chimioterapie, pentru care tratamentul în asociere cu paclitaxel nu este adecvată. colorectal cancercyramza, în asociere cu folfiri (irinotecan, acid folinic și 5‑fluorouracil), este indicat pentru tratamentul pacienților adulți cu cancer colorectal metastatic (ccrm) cu progresia bolii sau după un tratament anterior cu bevacizumab oxaliplatină și o fluoropirimidină. non-pulmonar cu celule mici cancercyramza în combinație cu docetaxel este indicat pentru tratamentul pacienților adulți cu local avansat sau metastatic cu celule non-mici cancer pulmonar cu progresia bolii după chimioterapie pe bază de platină. hepatocelular carcinomacyramza este indicat în monoterapie pentru tratamentul pacienților adulți cu avansate sau carcinom hepatocelular inoperabil care au un ser alfa fetoproteina (afp) ≥ 400 ng/ml și care au fost anterior tratați cu sorafenib.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lilly pharma fertigung und distrib. gmbh & co. kg - italia - ramucirumabum - conc. pt. sol. perf. - 10 mg/ml - anticorpi monoclonali inhibitori vegf/vegfr

Uniunea Europeană - română - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - sânii neoplasme - agenți antineoplazici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Uniunea Europeană - română - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

almac pharma services (ireland) limited - irlanda - ravulizumabum - conc. pt. sol. perf. - 1100 mg/11 ml - imunosupresoare imunosupresoare selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

almac pharma services (ireland) limited - irlanda - ravulizumabum - conc. pt. sol. perf. - 300mg/3ml - imunosupresoare imunosupresoare selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

boiron - franta - homeopate - sol. orala in recipient unidoza - homeopate cu indicatii terapeutice homeopate cu indicatii terapeutice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bilim pharmaceuticals a.?. - diclofenacum - picaturi oftalmice, solutie - 0,1%

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bilim ilac sanayi ve ticaret a.?. - tobramycinum - picaturi oftalmice, solutie - 0,3%

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

boiron - franta - homeopate - sol. orala in recipient unidoza - homeopate cu indicatii terapeutice homeopate cu indicatii terapeutice